Loading stock data…
IceCure Medical Ltd. (ICCM)
$2.21-0.02 (-0.90%)
Market ClosedLast close Sep 8
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IceCure Medical Ltd in the Healthcare sector is trading at $2.21 with a market capitalization of $10M. Wall Street consensus targets $22.67 (3 analysts), implying a +925.6% move over the next 12 months. The stock is currently near its 52-week low of $2.12, remaining 80.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 8 is oversold, raising the odds of a near-term bounce. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +925.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 8) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $911,000↓ | $1.28M↑ | $850,000↑ | $525,000↓ | $725,000 |
| Gross Profit | $295,000↓ | $600,000↑ | $277,000↑ | $131,000↓ | $218,000 |
| Operating Income | -$4.25M↓ | -$4.22M↓ | -$3.84M↓ | -$3.38M↑ | -$3.66M |
| Net Income | -$4.27M↓ | -$4.25M↓ | -$3.86M↓ | -$3.36M↑ | -$3.59M |
Peer Comparison
JNJUNHPFE
Fundamentals
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and inte...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-185.34%
Volume
Today's trading volume
54,003
Recent News
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as US ...
Company reports strong commercial momentum with expanding gross margins and advancing CHoICE study, despite widening net loss.
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript
Revenue surged 45% as U.S. breast cancer clearance drives commercial expansion.
IceCure Medical Ltd Q2 2026 Earnings Call Summary
Moby summary of IceCure Medical Ltd's Q2 2026 earnings call
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Establishment Labs (ESTA) delivered earnings and revenue surprises of -14.71% and +3.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally?
IceCure reported a 70% increase in its active U.S. commercial install base of ProSense systems.